MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia

Ramiro Garzon, Stefano Volinia, Chang Gong Liu, Cecilia Fernandez-Cymering, Tiziana Palumbo, Flavia Pichiorri, Muller Fabbri, Kevin Coombes, Hansjuerg Alder, Tatsuya Nakamura, Neal Flomenberg, Guido Marcucci, George A. Calin, Steven M. Kornblau, Hagop Kantarjian, Clara D. Bloomfield, Michael Andreeff, Carlo M. Croce

Research output: Contribution to journalArticlepeer-review

541 Scopus citations

Abstract

MicroRNAs (miRNAs) are small RNAs of 19 to 25 nucleotides that are negative regulators of gene expression. To determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute myeloid leukemia (AML), we evaluated the miRNA expression of CD34+ cells and 122 untreated adult AML cases using a microarray platform. After background subtraction and normalization using a set of housekeeping genes, data were analyzed using Significance Analysis of Microarrays. An independent set of 60 untreated AML patients was used to validate the outcome signatures using real-time polymerase chain reaction. We identified several miRNAs differentially expressed between CD34+ normal cells and the AML samples. miRNA expression was also closely associated with selected cytogenetic and molecular abnormalities, such as t(11q23), isolated trisomy 8, and FLT3-lJD mutations. Furthermore, patients with high expression of miR-191 and miR-199a had significantly worse overall and event-free survival than AML patients with low expression (overall survival: miR-191, P = .03; and miR-199a, P = .001, Cox regression). In conclusion, miRNA expression in AML is closely associated with cytogenetics and FLT3-lTD mutations. A small subset of miRNAs is correlated with survival.

Original languageEnglish
Pages (from-to)3183-3189
Number of pages7
JournalBlood
Volume111
Issue number6
DOIs
StatePublished - 15 Mar 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this